Graybug Vision Inc is a reputable company that upholds values and a corporate philosophy centered on innovation, growth, and patient-centric care. With a commitment to advancing the field of ocular therapeutics, Graybug Vision Inc focuses on developing transformative treatments for vision-threatening diseases. By utilizing cutting-edge technology and scientific expertise, the company strives to improve the quality of life for individuals suffering from chronic eye conditions. Graybug Vision Inc's dedication to research, collaboration, and delivering novel therapies underscores their mission to address unmet medical needs in the ophthalmic space, making them a trusted name in the industry.

Graybug Vision Inc is primarily present in the United States.

Graybug Vision Inc has achieved several significant milestones. The company successfully completed a Phase 1/2a clinical trial for its product candidate GB-102, demonstrating positive results in treating neovascular age-related macular degeneration. They also secured a partnership with Oxurion NV, a global biopharmaceutical company, for the development and commercialization of GB-102. In addition, Graybug Vision Inc received FDA Fast Track designation for GB-102, recognizing its potential to address an unmet medical need. These milestones highlight the company's commitment to advancing innovative treatments in ophthalmology and position Graybug Vision Inc as a promising player in the biopharmaceutical industry.

Graybug Vision Inc is a pharmaceutical company specializing in developing transformative therapies for vision-threatening diseases. Founded in 2011, the company is dedicated to improving the lives of patients suffering from age-related macular degeneration and other ocular conditions. Graybug Vision Inc's innovative approach involves providing sustained-release treatments that reduce the frequency of injections needed for therapies. With a team of experienced professionals and cutting-edge technology, Graybug Vision Inc is at the forefront of developing advanced ophthalmic treatments to address unmet medical needs. The company's commitment to research and development has positioned it as a promising player in the field of eye care.

Some of the major competitors of Graybug Vision Inc in the market include other companies operating in the ophthalmology sector such as Allergan plc, Novartis AG, and Regeneron Pharmaceuticals Inc.

Graybug Vision Inc is primarily active in the pharmaceutical and biotechnology industries.

Graybug Vision Inc is a biopharmaceutical company focused on developing transformative therapies for ocular diseases. Their business model revolves around utilizing their proprietary technologies to develop and commercialize innovative treatments for sight-threatening conditions like wet age-related macular degeneration and diabetic macular edema. By leveraging their unique platform, Graybug Vision aims to improve patient outcomes and offer long-lasting therapies that reduce the frequency of injections required for treatment. Through strategic partnerships and clinical research, the company strives to address critical unmet needs in ophthalmology and provide hope for patients suffering from vision-related ailments.

Graybug Vision KGV ir -0,16.

Graybug Vision KUV ir 0.

AlleAktien kvalitātes vērtējums Graybug Vision ir 1/10.

Pašreiz nevar aprēķināt apgrozījumu Graybug Vision.

gaidāmā Graybug Vision peļņa ir -30,64 milj. .

Graybug Vision Inc is a biopharmaceutical company specializing in the development of therapies for the treatment of chronic eye diseases. The company was founded in 2011 and is headquartered in Redwood City, California. Graybug Vision's business activities include research, development, manufacturing, and marketing of drugs for the treatment of eye diseases, including dry eye syndrome, age-related macular degeneration, glaucoma, and diabetic retinopathy. The company has developed a proprietary drug delivery system called "Sustained-Release Technology" that allows drugs to be delivered directly into the eye, achieving a continuous therapeutic effect. With this system, medications can be delivered over a longer period of time, reducing the need for frequent injections or drops. Graybug Vision currently has several products in clinical development, including GB-102 and GB-401 for the treatment of wet age-related macular degeneration, GB-103 for the treatment of glaucoma, and GB-401 for the treatment of diabetic retinopathy. GB-102 is a single-dose injection currently being tested in phase 2 clinical trials. It is intended to be injected into the eye once a month to achieve a continuous effect. The injection contains a drug called aflibercept, which is encapsulated in a gel using Graybug's sustained-release technology system. GB-102 has shown promising results in phase 1/2 study and is currently being further tested in phase 2b clinical trial. GB-103 is a long-acting glaucoma medication currently in preclinical development. It is intended to be the first medication on the market with a continuous effect lasting up to six months. GB-103 is intended to be injected directly into the vitreous humor of the eye, allowing for a higher concentration of the drug in the eye and improving treatment effectiveness. GB-401 is another product from Graybug Vision that is still in preclinical development. It is used for the treatment of diabetic retinopathy and is a one-time procedure using sustained-release technology in an implant form. The implant has sustained-release properties, including drug release. It is also biodegradable and is gradually absorbed by the body over time. Graybug Vision recently entered into a partnership with Ocumension Therapeutics to expand its injectable therapeutic platform in China and Asia and bring products to market. The partnership is expected to enable Graybug Vision to capture the Asian market and expand its global activities. Graybug Vision's business model is focused on the development and commercialization of innovative therapies for the treatment of eye diseases. The company relies on its proprietary drug delivery system to administer medications continuously in the eye, eliminating the need for frequent injections or drops. Graybug Vision is actively working on the development of additional therapies to improve treatment effectiveness and enhance the quality of life for patients with chronic eye diseases.

Graybug Vision izmaksā dividendes 0 , kas tiek izmaksātas reizes gadā.

Dividendes pašlaik nevar aprēķināt Graybug Vision vai uzņēmums nedod dividendes.

Graybug Vision ISIN ir US38942Q1031.

Graybug Vision WKN ir A2QDGM.

Graybug Vision simbols ir GRAY.

Pēdējo 12 mēnešu laikā Graybug Vision maksāja dividendes apmērā. Tas atbilst aptuveni dividendes ražībai. Nākamajos 12 mēnešos Graybug Vision plāno maksāt dividendes 0 apmērā.

Graybug Vision pašreizējā dividendu rentabilitāte ir .

Graybug Vision maksā dividendes ceturksnī. Tās tiek izmaksātas mēnešos .

Graybug Vision pēdējo 0 gadu laikā katru gadu izmaksāja dividendes.

Nākamajiem 12 mēnešiem tiek prognozētas dividendes apmērā 0 . Tas atbilst dividendes ražībai 0 %.

Graybug Vision tiek piešķirts nozarei "Veselība".

Lai saņemtu pēdējo dividendu Graybug Vision apmērā 0 , kas tika izmaksāta 12.02.2025., tev akcija bija jāpatur depozītā līdz Ekss dienai, kas bija 12.02.2025..

Pēdējās dividendes izmaksa notika 12.02.2025..

Gadā 2024, Graybug Vision izmaksāja 0 dividendes.

Graybug Vision dividendes tiek izmaksātas .